Atossa Therapeutics, Inc. (ATOS) financial statements and ratios from SEC XBRL: revenue $2.38M (TTM), net margin -1462.8%, revenue growth -41.3% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $2.38M |
| Net Margin | -1462.8% |
| Revenue Growth (YoY) | -41.3% |
| EPS Growth (YoY) | 1920.0% |
| FCF Growth (YoY) | 41.5% |
| Price / Book | 0.94 |
| Price / Sales | 17.88 |
| FCF Yield | -227.8% |
| Altman Z-Score | -7.25 (distress) |
| Sector P/E (Healthcare) | 21.7 |
ATOS overview · ATOS earnings · ATOS KPIs · ATOS investor relations · ATOS ownership · ATOS peers · ATOS filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.